Role of omeprazole in prevention and treatment of postendoscopic variceal sclerotherapy esophageal complications. Double-blind randomized study
Autor: | D. K. Bhargava, Pramod Kumar Garg, Sandeep Singh Sidhu |
---|---|
Rok vydání: | 1995 |
Předmět: |
Adult
Male medicine.medical_specialty Adolescent Physiology medicine.drug_class Proton-pump inhibitor Hemorrhage Placebo Esophageal Diseases Esophageal and Gastric Varices Gastroenterology Double-Blind Method Recurrence Internal medicine Hypertension Portal Sclerotherapy Medicine Humans Esophagus Omeprazole Ulcer Aged Aged 80 and over business.industry Esophageal disease Middle Aged medicine.disease Surgery Esophageal Ulcer medicine.anatomical_structure Esophageal stricture Esophageal Stenosis Portal hypertension Female Esophagoscopy business medicine.drug |
Zdroj: | Digestive diseases and sciences. 40(7) |
ISSN: | 0163-2116 |
Popis: | Endoscopic variceal sclerotherapy-related esophageal complications are quite common. The potential efficacy of omeprazole in the prevention and treatment of postsclerotherapy esophageal complications was evaluated in 47 patients with portal hypertension in a randomized, placebo-controlled study. Twenty-one patients in the omeprazole group and 23 patients in the placebo group completed the study. The two treatment groups were similar in regards to the etiology of portal hypertension, Child's class, and clinical characteristics. Esophageal ulcers developed in 16 patients in the omeprazole group (2.43 ulcers/patient) and 18 patients in the placebo group (2.39 ulcers/patient). Most of the ulcers (>90%) healed within 14 days in each group. Esophageal strictures requiring dilatation developed in two and one patient in the omeprazole and placebo groups, respectively. There was no statistically significant difference in regards to the complication rate between the two groups. We conclude that omeprazole is not effective for the prevention or treatment of postsclerotherapy esophageal complications. |
Databáze: | OpenAIRE |
Externí odkaz: |